ReviewPLoS neglected tropical diseases2026
Advances in vaccine development through the controlled human infection models for hookworm and schistosomiasis.
Review in PLoS neglected tropical diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Controlled human infection models can play an important role in vaccine development, particularly for neglected tropical diseases such as helminth infections. Currently, controlled infection models have been established for schistosomiasis and hookworm. This review highlights the developments in the controlled human schistosomiasis infection model (CHI-S) and the controlled human hookworm infection model (CHHI) and their contributions to vaccine development. In general, both models are considered safe and well-tolerated. Measures to decrease risk of potential adverse events were taken when developing the models. For both models, production of challenge agents follows the principles of Good Manufacturing Practice. Both models have proven to reliably detect infection and can be used to assess efficacy of immunization strategies. While hookworms and schistosomes are both helminths, the controlled human infection (CHI)-studies have also highlighted differences between these pathogens. Notably, schistosomiasis seems to induce more, dose-dependent, systemic symptoms, whereas in hookworm models skin symptoms are much more prominent. Infection levels for schistosomiasis are therefore limited and lower than those usually seen in endemic populations, whereas for hookworm it is possible to reach levels comparable to mild-moderate intensity infection in the field. Host responses to short-term infection were also different: short-term schistosome infection induced immune-tolerance, whereas short-term infection with hookworm larvae seems to induce a more pro-inflammatory response compared to that seen in the adult worms. Most studies have been performed in naïve non-endemic populations, however, currently the models are being expanded to endemic areas. This has raised new questions around the impact of non-native strains of parasites or vectors to the endemic parasite strains and the environment. Studies in endemic areas, however, will significantly contribute towards understanding the immunology of these helminth infections in pre-exposed individuals. In general, the success of these established models is encouraging to the further development of controlled human helminth infection models.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.